Due to the onset of Juvenile Idiopathic Arthritis (JIA) during adolescence the patient was treated for three years with an anti-Tumor Necrosis Factor-alpha drug, etanercept, and the authors observed a significative reduction of insulin dose although a well-controlled diabetes, normalization of her inflammatory markers, and inactivation of the arthritis. Here, INS is linked to juvenile idiopathic arthritis.